LDS/Medical Tests/Chronic Lymphocytic Leukemia (CLL), FISH, Bone Marrow

Chronic Lymphocytic Leukemia (CLL), FISH, Bone Marrow

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a neoplasm of mature B lymphocytes with characteristic morphology and immunophenotype. It is the most common adult leukemia in the western countries. While CLL primarily involves the blood, and bone marrow, SLL initially involves lymph nodes. Over time, however, CLL typically involves lymph nodes, spleen and other tissue, while SLL progresses to involve the bone marrow and blood. As CLL/SLL is clinically indolent, often diagnosed on routine CBC it may not be possible to determine if the neoplasm arose in the bone marrow or lymph nodes, hence the designation CLL/SLL.

The Rai and Binet staging systems, which were developed ~40 years ago, are still valid and are used to define the disease extent at the time of diagnosis. However, in the recent past, it was noted that approximately three quarters of newly diagnosed CLL patients are diagnosed at the Rai 0/Binet A stage. The clinical risk and prognosis are difficult to determine by these staging systems alone, and require the use of biomarkers.

In the recent past, the mutational status of Immunoglobulin Heavy Chain Variable region (IGHV) and recurrent cytogenetic abnormalities have been found to be powerful prognostic indicators in CLL. Interphase fluorescent in situ hybridization (FISH) has several advantages and hence, is widely used to detect these cytogenetic abnormalities. FISH does not require cell cultures and can be performed on a variety of specimens including blood, bone marrow aspirate and formalin fixed paraffin embedded tissue (FFPET) blocks. FISH is easy to perform and analyze, and has a significantly better turn around time (TAT) than conventional karyotype studies. FISH probes used in CLL panel include 11q, 12, 13q, and 17p. Some labs also include IGH-CCND1 dual color dual fusion probe as a part of this panel to exclude mantle cell lymphoma. Del(17p) and del(11q) portend a poor outcome while isolated del(13q) is associated with a more favorable outcome. Trisomy 12 confers an intermediate risk. Del(17p) also predicts a lack of response to fludarabine-containing therapeutic regimens.

The findings of the FISH studies are being combined with other clinical, biochemical, genetic and molecular markers into a single risk score for patients with CLL. Examples include the International Prognostic Index, German CLL Index, and MD Anderson Prognosis Score. The 2018 international workshop on chronic lymphocytic leukemia (iwCLL) guidelines recommend FISH studies for del(13q), del(11q), del(17p), add (12) as baseline evaluation of all patients with CLL.

  • As an aid in diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma
  • Risk stratification and prognostic evaluation of chronic lymphocytic leukemia/small lymphocytic lymphoma at diagnosis and relapse
Depends on the findings but; however, any abnormalities would be reported with clinical interpretation such an example below EXAMPLE: These abnormal results indicate trisomy 12 in 50% of nuclei and a 6q deletion in 50% of nuclei. Combination of these genomic abnormalities is associated with an intermediate to poor prognosis.

The result is within normal limits for the CLL FISH panel

Fluorescence in situ hybridization (FISH).

Bone marrow in green top (sodium heparin) tube.

Stability

  • Room: 48 hours
  • Refrigerated: 48 hours
  • Frozen: unacceptable

Paraffin embedded tissue blocks and/or unstained sections on a glass slide may also be acceptable.

Serum beta-2 microglobulin (B2M) levels, IGHV gene mutation status, TP53 gene mutation analysis, and detection of CD38 and ZAP-70 expression by flow cytometry.
2-3 Days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login